2022
Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer
Saeed N, Jin L, Amini A, Verma V, Lester-Coll N, Chen P, Decker R, Park H. Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer. American Journal Of Clinical Oncology 2022, 46: 66-72. PMID: 36662872, DOI: 10.1097/coc.0000000000000974.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage I non-small cell lung cancerOverall survivalCell lung cancerLung cancerStereotactic body radiation therapyNational Cancer DatabaseLog-rank testBody radiation therapyOptimal fractionation scheduleMultivariable modeling techniquesOS benefitHypofractionated radiotherapySurvival impactMultivariable analysisCox regressionCancer DatabaseRetrospective analysisFractionation schedulesRadiation therapyHFRTPatientsCFRTRadiotherapyKaplan-Meier estimator
2021
Clinical Outcomes and Safety Profile in the Treatment of Synchronous Nonmetastatic Lung Tumors With Stereotactic Body Radiation Therapy
Raju SC, Peters GW, Decker RH, Park HS. Clinical Outcomes and Safety Profile in the Treatment of Synchronous Nonmetastatic Lung Tumors With Stereotactic Body Radiation Therapy. Practical Radiation Oncology 2021, 12: e110-e116. PMID: 34861443, DOI: 10.1016/j.prro.2021.11.006.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyPrimary lung tumorsSynchronous primary lung tumorsAdverse events gradeCommon Terminology CriteriaBody radiation therapyLung tumorsNew primaryTerminology CriteriaOverall survivalClinical outcomesLung cancerRadiation therapyEvents gradeEarly-stage primary lung cancerMedian progression-free survivalEffective doseDistant failure ratesLocal failure rateMedian overall survivalMedian total dosePrimary lung cancerProgression-free survivalPatterns of recurrenceNonmetastatic lung cancerOptimal Timing of SBRT for Treatment of Oligometastatic Disease: A Single Institution Retrospective Analysis
Gao S, Yu J, Park H, Decker R. Optimal Timing of SBRT for Treatment of Oligometastatic Disease: A Single Institution Retrospective Analysis. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e476-e477. DOI: 10.1016/j.ijrobp.2021.07.1324.Peer-Reviewed Original ResearchCurative-intent stereotactic body radiation therapyStereotactic body radiation therapyUpfront systemic therapyKarnofsky performance scoreProgression-free survivalSystemic therapyOverall survivalOligometastatic diseaseSequential therapyWorse survivalOligometastatic settingConcurrent therapyImproved survivalHigher Karnofsky performance scoreSingle-institution retrospective analysisOptimal timingCox proportional hazards modelExtracranial metastatic lesionsImproved overall survivalPrimary tumor locationMajority of patientsConcurrent systemic therapyMultivariate Cox analysisBody radiation therapyProportional hazards model
2020
Development and Validation of a Deep Learning Algorithm to Predict Radiation Pneumonitis and Esophagitis Following Lung Stereotactic Body Radiation Therapy
Chang E, Du J, Decker R, Yu J, Park H, Aneja S. Development and Validation of a Deep Learning Algorithm to Predict Radiation Pneumonitis and Esophagitis Following Lung Stereotactic Body Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e14. DOI: 10.1016/j.ijrobp.2020.02.496.Peer-Reviewed Original ResearchLung stereotactic body radiation therapyStereotactic body radiation therapyBody radiation therapyRadiation pneumonitisRadiation therapy
2019
Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma
Kann BH, Verma V, Stahl JM, Ross R, Dosoretz AP, Shafman TD, Gross CP, Park HS, Yu JB, Decker RH. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma. Radiotherapy And Oncology 2019, 134: 44-49. PMID: 31005223, DOI: 10.1016/j.radonc.2019.01.027.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaStereotactic body radiation therapyProgression-free survivalEarly-stage non-small cell lung carcinomaOperable patientsBody radiation therapyCell lung carcinomaOverall survivalLocal failureLung carcinomaRadiation therapyInoperable early stage non-small cell lung carcinomaDefinitive stereotactic body radiation therapyLack of resectionPoor surgical candidacyRetrospective cohort studyKaplan-Meier methodologyHigher overall survivalDisease-related outcomesMulti-institutional analysisDocumentation of patientsStandard of careMulti-institutional studyCohort studyInoperable patients
2018
Systemic Therapy with Stereotactic Body Radiation Therapy (SBRT) for Early-Stage Non-Small Cell Lung Carcinoma (NSCLC): A Multi-institutional Analysis
Kann B, Miccio J, Stahl J, Verma V, Dosoretz A, Park H, Shafman T, Gross C, Yu J, Decker R. Systemic Therapy with Stereotactic Body Radiation Therapy (SBRT) for Early-Stage Non-Small Cell Lung Carcinoma (NSCLC): A Multi-institutional Analysis. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s10-s11. DOI: 10.1016/j.ijrobp.2018.06.119.Peer-Reviewed Original Research
2017
Dose-Volume Predictors of Esophagitis After Thoracic Stereotactic Body Radiation Therapy
Harder EM, Chen Z, Park HS, Mancini BR, Decker RH. Dose-Volume Predictors of Esophagitis After Thoracic Stereotactic Body Radiation Therapy. American Journal Of Clinical Oncology 2017, 40: 477-482. PMID: 26017483, DOI: 10.1097/coc.0000000000000195.Peer-Reviewed Original ResearchConceptsStepwise selection techniqueRadiation therapyThoracic stereotactic body radiation therapyStereotactic hypofractionated radiation therapyStereotactic body radiation therapyDose-volume predictorsNormal tissue complication probabilityHypofractionated radiation therapyMultivariate logistic regressionProbability estimatesBody radiation therapyPlanning target volumeEsophageal toxicityEsophagitis ratesCTCAE v4.0Dosimetric predictorsPulmonary tumorsInstitutional databaseRadiotherapy parametersStage I Lung SBRT Clinical Practice Patterns
Corso CD, Park HS, Moreno AC, Kim AW, Yu JB, Husain ZA, Decker RH. Stage I Lung SBRT Clinical Practice Patterns. American Journal Of Clinical Oncology 2017, 40: 358-361. PMID: 25503436, DOI: 10.1097/coc.0000000000000162.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyNational Cancer DatabaseStage I non-small cell lung cancer patientsUse of SBRTNon-small cell lung cancer patientsCell lung cancer patientsStage I NSCLCMajority of patientsClinical practice patternsLung cancer patientsBody radiation therapyMedian BED10SBRT useDosing guidelinesRetrospective studyCancer patientsPrescription trendsCancer DatabasePractice patternsRadiation therapyPatientsDose prescriptionGyRegimensCommon prescription
2016
Trends in stereotactic body radiation therapy for stage I small cell lung cancer
Stahl JM, Corso CD, Verma V, Park HS, Nath SK, Husain ZA, Simone CB, Kim AW, Decker RH. Trends in stereotactic body radiation therapy for stage I small cell lung cancer. Lung Cancer 2016, 103: 11-16. PMID: 28024690, DOI: 10.1016/j.lungcan.2016.11.009.Peer-Reviewed Original ResearchConceptsStage I small cell lung cancerNational Cancer Data BaseSmall cell lung cancerCell lung cancerMultivariable logistic regressionSBRT utilizationLung cancerDose prescriptionLogistic regressionStereotactic body radiation therapyInitial treatment allocationClinical stage IDefinitive surgical managementAdministration of chemotherapyKaplan-Meier methodBody radiation therapyRadiation therapy utilizationSBRT useChemotherapy useInoperable patientsMedian survivalChemotherapy administrationOverall survivalSurgical managementTherapy utilizationElderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients
Mancini BR, Park HS, Harder EM, Rutter CE, Corso CD, Decker RH, Husain ZA. Elderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients. Lung Cancer 2016, 97: 22-27. PMID: 27237023, DOI: 10.1016/j.lungcan.2016.04.011.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerEarly-stage non-small cell lung cancerStereotactic body radiation therapyNon-elderly patientsElderly patientsDistant controlOverall survivalYounger patientsInoperable early-stage non-small cell lung cancerUse of SBRTStage non-small cell lung cancerLocal controlMultivariable Cox proportional hazards analysisCox proportional hazards analysisGrade 5 toxicityNon-elderly cohortProportional hazards analysisCell lung cancerRisk of complicationsRate of efficacyBody radiation therapyLogistic regression analysisLate gradeAcute gradeSurgical resectionPulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy
Harder EM, Park HS, Chen Z, Decker RH. Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy. Practical Radiation Oncology 2016, 6: e353-e359. PMID: 27156424, DOI: 10.1016/j.prro.2016.01.015.Peer-Reviewed Original ResearchConceptsMean lung doseStereotactic body radiation therapyRisk of gradeRadiation pneumonitisMultivariable logistic regressionBody radiation therapyDosimetric predictorsRadiation therapyMaximum doseLogistic regressionRP rateBest dosimetric predictorCardiac dosimetric parametersDose-volume predictorsPercent of lungVolume of lungGross tumor volumeBackward stepwise eliminationLung V10Lung doseMean doseTotal lungUnivariate analysisPulmonary volumesTumor volume
2015
Higher Facility Case Volume of Stereotactic Body Radiation Therapy Is Associated With Improved Overall Survival in Clinical Stage I Non-Small Cell Lung Cancer
Park H, Wang E, Corso C, Rutter C, Wilson L, Kim A, Gross C, Yu J, Decker R. Higher Facility Case Volume of Stereotactic Body Radiation Therapy Is Associated With Improved Overall Survival in Clinical Stage I Non-Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: s186-s187. DOI: 10.1016/j.ijrobp.2015.07.447.Peer-Reviewed Original ResearchSurvival Comparison of 3 Versus 4-5 Fractions for Stereotactic Body Radiation Therapy in Stage I Non-Small Cell Lung Cancer
Park H, Corso C, Rutter C, Kim A, Yu J, Husain Z, Decker R. Survival Comparison of 3 Versus 4-5 Fractions for Stereotactic Body Radiation Therapy in Stage I Non-Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: s100. DOI: 10.1016/j.ijrobp.2015.07.240.Peer-Reviewed Original ResearchAngiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy
Harder EM, Park HS, Nath SK, Mancini BR, Decker RH. Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy. Practical Radiation Oncology 2015, 5: e643-e649. PMID: 26412341, DOI: 10.1016/j.prro.2015.07.003.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyACE inhibitor useNonsteroidal anti-inflammatory drugsAngiotensin receptor blockersRadiation pneumonitisSymptomatic radiation pneumonitisInhibitor useBody radiation therapyAnti-inflammatory drugsRadiation therapyReceptor blockersACE inhibitorsAngiotensin-converting enzyme inhibitor useACE inhibitor usersCommon Terminology CriteriaEnzyme inhibitor usePrimary lung cancerNormal lung tissuesAvailable medical recordsCox proportional hazardsPulmonary doseTerminology CriteriaInhibitor usersAdverse eventsOverall survival